Atossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific Advisor

SEATTLE, March 27, 2018 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced that Per Hall, MD, Ph.D., has been appointed as Scientific Advisor.

Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is the Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm, Sweden. Dr. Hall is leading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women (karmastudy.org). The KARMA Cohort is regarded as one of the best characterized breast cancer cohorts in the world and serves as a resource for studies about breast cancer risk assessment and prevention. He is also leading the Karisma Intervention Study, which is studying the change in mammographic breast density (MBD) in women taking various doses of oral tamoxifen. Dr. Hall is the principle investigator on the upcoming Phase 2 study of Atossa’s proprietary topical Endoxifen to treat MBD.

"Dr. Hall is a welcome addition to our Scientific Advisory Board which is composed of world-class experts in breast cancer research,” said Dr. Steve Quay, President and CEO of Atossa. “Dr. Hall has undertaken some of the most comprehensive and important clinical studies in breast cancer prevention and will be a critical addition to our team as we advance our proprietary Endoxifen into Phase 2 studies.”

About Atossa Genetics

Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
Phone 206 556-3238
[email protected]

Investor Relations Contact

Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Phone (516) 222-2560
[email protected]

Source: Atossa Genetics Inc.